Company intelligence / Profile preview

Shenzhen Bioeasy Biotechnology

Shenzhen, Guangdong, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~389
Development stage: Commercial

Overview

Bioeasy has a broad commercial portfolio of validated rapid diagnostic kits used worldwide in food safety monitoring as well as select human health applications such as COVID‑19 antigen testing. Their products are certified to international standards including CE mark for certain medical devices.

Therapeutic areas: OtherPsychiatryGastroenterologyInfectious Diseases
Modalities: Immunochromatography-based rapid test kitsELISA-based diagnosticsPCR-based diagnostics
Industry: Molecular Diagnostics

Drug pipeline

1 asset

2019-nCoV Ag

Commercial

Indications: COVID-19 diagnosis

Partnerships

AOAC InternationalIAFP

Beyond the preview

Go deeper on Shenzhen Bioeasy Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Bioeasy Biotechnology.

Explore the full profile